Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 27, 2026International Journal of Innovative Technologies in Social ScienceOpen Access

Polypharmacy in older adults linked to ~62% higher five-year mortality and increased adverse drug events.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Increasing multimorbidity and polypharmacy in aging populations heighten risks of adverse drug reactions, prescribing cascades, and functional decline, necessitating evidence-based pharmacotherapy optimization.

Population

Older adults

Design

Systematic review

Key result

Polypharmacy in older adults significantly increases five-year mortality (41.57% vs 31.90%, HR 1.62) and is associated with higher rates of adverse drug events, falls, and cognitive decline.

Authors

JSJustyna SłowikISIzabela SieradzkaKWKatarzyna Wajda

Discussion

Loading...

Member takes

Overview

Emphasizes distinguishing appropriate from inappropriate polypharmacy; reinforces deprescribing and interdisciplinary optimization in geriatric practice.

Key Points

  • This review investigates the prevalence and consequences of polypharmacy in older adults, focusing on appropriate vs. inappropriate medication use.
  • Comprehensive systematic review of existing literature on geriatric polypharmacy
  • Analysis of epidemiology, pathophysiology, clinical outcomes, and therapy optimization strategies
  • Evaluation of evidence-based interventions for medication management
  • Inappropriate polypharmacy was associated with increased adverse drug reactions and functional decline
  • Evidence-based optimization strategies include medication review and interdisciplinary collaboration
  • Highlighting the need for individualized patient-centered care to mitigate risks of polypharmacy

Study Design

Type

Systematic Review

Structured PICO

P
Population
A systematic review of 58 studies evaluating the epidemiology, clinical consequences, and optimization strategies for polypharmacy in adults aged 65 and older.
E
Exposure
Pharmacotherapy optimization strategies (including medication review, deprescribing, interdisciplinary collaboration, and individualized patient-centered care)

Main Result

Hazard Ratio: 1.62

Absolute Event Rate: 41.57% vs 31.9%

This systematic review highlights the mechanisms and clinical consequences of inappropriate polypharmacy in older adults and emphasizes evidence-based strategies for pharmacotherapy optimization.

Limitations

  • Lack of universal applicability of evaluation tools across different genetic and environmental populations
  • Brief pharmacist interventions suffer from poor temporal retention without continuous integration and cooperation with local community health units

Cite This Study

Słowik et al. (2026) conducted a systematic review in Polypharmacy. Polypharmacy vs. Lighter pharmacological regimens was evaluated on Five-year mortality (HR 1.62). Polypharmacy in older adults significantly increases five-year mortality (41.57% vs 31.90%, HR 1.62) and is associated with higher rates of adverse drug events, falls, and cognitive decline.

synapsesocial.com/papers/6a6794fcbb2605d1235fba18https://doi.org/10.31435/ijitss.3(51).2026.5936
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A REVIEW ON POLYPHARMACY IN GERIATRIC PATIENT2026
  2. 2Navigating Polypharmacy in Elderly Psychiatric Patients: A Review of the Literature2025 · 2 citations
  3. 3MULTIMORBIDITY AND POLYPHARMACY IN OLDER ADULTS: CHALLENGES FOR HEALTHCARE SYSTEMS AND STRATEGIES FOR MEDICATION OPTIMIZATION — A NARRATIVE REVIEW2026
  4. 4Polypharmacy in the older patient2025
  5. 5A concerning trend in geriatric pharmacy that merits evidence-based intervention2022